N@N

FOREST LABORATORIES INC (NYSE:FRX), Up By 6.61% ($2.18) From $33.000 After BUYINS.NET Report Predicted Stock Would Go Up Due To

^{Published on 2011-05-19 05:21:10 - WOPRAI}
 

May 19, 2011 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Monday, March 21st 2011 stating that FOREST LABORATORIES INC (NYSE:FRX) was expected to go Up due to the Bullish conditions presented in the following report. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=frx&id=154830

At the time this story was written, FOREST LABORATORIES INC (NYSE:FRX) is Up By $2.18 (6.61%) since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following specific fundamental or technical events may follow a predictable pattern. Many companies stock price histories show random or unpredictable movements around certain events. But some seem to repeat the same pattern quarter after quarter, year after year. We use powerful computers to uncover those events and correlations to generate predictions with high probabilities of generating very specific returns within very specific time periods.

The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

FOREST LABORATORIES INC (NYSE:FRX) - Forest Laboratories, Inc. develops, manufactures, and sells branded and generic forms of ethical drug products. Its principal products include Lexapro for the treatment of depression in adults and adolescents, and generalized anxiety disorder in adults; Namenda for the treatment of Alzheimer's disease; Bystolic for the treatment of hypertension; and Savella for the management of fibromyalgia. The company is also developing various products, including Daxas, which is in Phase III clinical trial for the treatment of chronic obstructive pulmonary disease (COPD); Ceftaroline that has completed Phase II clinical trial for the treatment of community acquired bacterial pneumonia; ceftazidime/NXL104 combination, which is in Phase II clinical trial; and Linaclotide that is in the Phase III clinical trial for the treatment of constipation-predominant irritable bowel syndrome and chronic constipation. In addition, it is developing Aclidinium, which is in the Phase III clinical trial as an inhaled therapy for COPD; LAS100977 that is in Phase II clinical trial for the treatment of asthma and COPD; Cariprazine, which is in Phase III clinical trial for the treatment of schizophrenia, bipolar mania, and other psychiatric conditions; F2695 that is in pre-clinical stage for the treatment of depression; Radiprodil, which is in Phase II clinical trial for the treatment of chronic pain and other central nervous system conditions; and mGLuR1/5 Compounds for the treatment of anxiety, depression, and other CNS conditions. Forest Laboratories, Inc. sells its products through independent distributors to physicians, pharmacies, hospitals, and managed care and other healthcare organizations. The company was founded in 1956 and is based in New York, New York.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor market-maker surveillance system tracking Level II market-makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 30 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies specifically for this report, but may have been compensated up to $1,200 per month in the past for unrelated data or report services. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net